Myrexis, Inc. MYRX

Company Overview

Myrexis, Inc. (NASDAQ: MYRX) was a U.S.-based biopharmaceutical company focused on the discovery and development of small-molecule therapeutics for cancer and autoimmune diseases. The company operated within the biotechnology and specialty pharmaceuticals industries, concentrating primarily on oncology drug candidates derived from its medicinal chemistry and translational research capabilities. Its principal value drivers historically included proprietary drug-development programs, intellectual property assets, and partnerships related to oncology compounds.

The company originated as Myriad Pharmaceuticals, Inc., a division of Myriad Genetics, Inc., before being spun off as an independent publicly traded company in 2009. Following the separation, Myrexis concentrated on advancing a pipeline of experimental therapeutics, including compounds targeting metastatic cancer and hematologic malignancies. Public filings and market disclosures indicate that the company later reduced operations substantially after clinical setbacks and financing constraints. Data regarding any continuing commercial operations after the mid-2010s is inconclusive based on available public sources.